BIB Ultra Nasdaq Biotechnology Proshares
- 51.120
- -1.039-1.99%
Marty Makary and Jay Bhattacharya Clear Senate Hurdles to Lead FDA and NIH
Reported Earlier, AstraZeneca's TAGRISSO Data From LAURA, SAVANNAH, And ORCHARD Trials Highlight Continued Survival Gains And Expanded Role in EGFR+ Lung Cancer
Amgen Options Trading: A Deep Dive Into Market Sentiment
Trump to Nominate Acting CDC Director Monarez to Lead Agency - Report
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Notable Healthcare Headlines for the Week: Pfizer, Sanofi, Sarepta Therapeutics and Medtronic in Focus
Key Deals This Week: Google, Nvidia, EsoBiotec SA, Coinbase Global and More
After the new person in charge took office, has AstraZeneca officially announced significant actions in China?
① Last night, AstraZeneca announced a series of investment plans in China, totaling 2.5 billion USD, which includes opening a research and development center and reaching agreements with several biotech companies; ② Industry experts believe that this series of "combined moves" is an attempt by the new leadership to refresh AstraZeneca and increase its bet on its second-largest market; ③ Some experts also remind that the investigation and results concerning AstraZeneca by relevant departments are still pending.
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
Top 10 S&P 500 Performers of 2025 All Returned Over 20% as the Broader Index Struggles
Democrats Warn Trump About Consequences of HIV Prevention Cuts
10 Health Care Stocks Whale Activity In Today's Session
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps
Today's Pre-Market Movers and Top Ratings | FDX, NKE, QUBT and more
Alnylam Pharmaceuticals Shares Are Trading Higher After the Company Secured FDA Approval Pf SNDA for Its RNAi Therapeutic, AMVUTTRA ,for Treatment of ATTR-CM in Adults.